APP Monoclonal Antibody

This gene encodes a cell surface receptor and transmembrane precursor protein that is cleaved by secretases to form a number of peptides. Some of these peptides are secreted and can bind to the acetyltransferase complex APBB1/TIP60 to promote transcriptional activation, while others form the protein basis of the amyloid plaques found in the brains of patients with Alzheimer disease. In addition, two of the peptides are antimicrobial peptides, having been shown to have bacteriocidal and antifungal activities. Mutations in this gene have been implicated in autosomal dominant Alzheimer disease and cerebroarterial amyloidosis (cerebral amyloid angiopathy). Multiple transcript variants encoding several different isoforms have been found for this gene.

Introducing the APP Monoclonal Antibody, a cutting-edge solution designed to revolutionize the field of biomedical research. This innovative product is meticulously crafted to target and detect amyloid precursor protein (APP), a key player in the pathogenesis of various neurodegenerative disorders.

The APP Monoclonal Antibody boasts exceptional specificity and sensitivity, enabling researchers to accurately identify and quantify APP in biological samples. Its advanced monoclonal antibody technology ensures reliable and reproducible results, facilitating precise investigations into the intricate mechanisms underlying neurodegenerative diseases.

Crafted with utmost precision, this antibody exhibits remarkable affinity towards APP, allowing for efficient and precise detection. Its robust performance is further enhanced by its compatibility with a wide range of experimental techniques, including immunohistochemistry, immunofluorescence, and Western blotting.

The APP Monoclonal Antibody is meticulously manufactured in state-of-the-art facilities, adhering to stringent quality control measures. Each batch undergoes rigorous testing to ensure consistent performance, guaranteeing reliable and reproducible results for researchers worldwide.

This groundbreaking product is poised to revolutionize the field of biomedical research, empowering scientists and clinicians alike to unravel the complexities of neurodegenerative disorders. With its unparalleled specificity, sensitivity, and compatibility, the APP Monoclonal Antibody is an indispensable tool for those seeking to advance our understanding of these debilitating conditions.

Invest in the future of biomedical research with the APP Monoclonal Antibody and unlock new insights into the mechanisms driving neurodegenerative diseases.